by WorldTribune Staff, October 30, 2022
The CDC pressured U.S. regulators to approve Covid-19 boosters without clinical trial data, according to emails obtained by a government watchdog group.
Emails obtained by Judicial Watch
show that, in early August 2021, the CDC contacted the FDA saying that they wanted authorization for Moderna and Pfizer boosters as data began showing that the vaccines authorized under emergency use authorization (EUA) weren’t working as well as initially promoted.
The conversation took place on a call that was described by Dr. Phil Krause, a top FDA official, to several other FDA workers.
“Take a deep breath before reading this next paragraph. On that call, the CDC evidently stated that they will assemble all the data they are aware of on third dosing in this setting and send it to us in the hope that we will (very soon) authorize the third dose for immunocompromised as part of the EUA,” Krause wrote in the Aug. 5, 2021, email.
At the time, no boosters had been authorized and no clinical data were available for the additional shots.
“These FDA records further document top officials’ concerns about the controversial Covid-19 booster shots,” said Judicial Watch President Tom Fitton. “That it has taken months and a federal lawsuit to uncover this critical material is a scandal.”
The emails show that “the CDC wanted the booster approved without a trial,” Dr. Jay Bhattacharya, a professor of medicine at Stanford University, wrote on Twitter.
In the emails obtained by Judicial Watch, Krause was responding to Doran Fink, who also works for the FDA’s Center for Biologics Evaluation and Research, charged with evaluating vaccines.
Fink sent a post that had been made to an infectious diseases forum regarding whether doctors should be giving additional vaccine doses to patients with compromised immune systems despite the lack of authorization.
Dr. Richard Nathan of Idaho had written that other countries, including Israel, had cleared boosters: “Pfizer recommends it and I trust their guidance over the turmoil at our federal agencies. With millions of doses of vaccine set to expire, you should do what you think is best for your patients. I can’t believe you would get pushback from anyone. Keep in mind, nearly everyone in this group is six to seven months out from the second dose of the vaccine and many have significant daily exposure to the virus."
Fink said the post “accurately reflects more widespread thinking that I am hearing in other forums as well,” including among doctors who advise the CDC on vaccines.
“Providers are losing confidence in FDA/CDC to do the right thing for their patients,” Fink said.
Less than two weeks later, the FDA authorized boosters for certain people, including the immunocompromised.
The FDA said that “a thorough review of the available data” concluded the group “may benefit” from a third dose.
Pfizer and Moderna hadn’t completed trials at the time. The only data cited on efficacy were from two studies, one conducted by French researchers and another by Canadian researchers.
“As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of Covid-19 vaccine at this time,” Dr. Janet Woodcock, the FDA’s top official said in an email.
But just weeks later, Woodcock and Dr. Rochelle Walensky, the CDC’s top official, signed onto a joint statement saying that vaccine protection was waning and that boosters “will be needed to maximize vaccine-induced protection and prolong its durability.”
In September 2021, the FDA and CDC authorized Pfizer boosters for many other Americans. The authorization was expanded to Moderna and Johnson & Johnson shots, and virtually all other Americans, later in the year.
Krause and Dr. Marion Gruber resigned from their positions because of opposition to the booster strategy.
An earlier tranche of emails obtained by Judicial Watch showed that Gruber was “very concerned” in late August 2021 about pressure from companies such as Pfizer over vaccine authorization.
“We need to be given time to consider their data and cannot be pushed by these companies and, for that matter the Administration, who try to impose timeless [sic] that make no sense,” Gruber wrote to Dr. Peter Marks, a top FDA official.
Action . . . . Intelligence . . . . Publish